The DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.
Getting TRAIL back on track for cancer therapy
Open accessAbstract
Unlike other members of the TNF superfamily, the TNF-related apoptosis-inducing ligand (TRAIL, also known as Apo2L) possesses the unique capacity to induce apoptosis selectively in cancer cells in vitro and in vivo. This exciting discovery provided the basis for the development of TRAIL-receptor agonists (TRAs), which have demonstrated robust anticancer activity in a number of preclinical studies. Subsequently initiated clinical trials testing TRAs demonstrated, on the one hand, broad tolerability but revealed, on the other, that therapeutic benefit was rather limited. Several factors that are likely to account for TRAs' sobering clinical performance have since been identified. First, because of initial concerns over potential hepatotoxicity, TRAs with relatively weak agonistic activity were selected to enter clinical trials. Second, although TRAIL can induce apoptosis in several cancer cell lines, it has now emerged that many others, and importantly, most primary cancer cells are resistant to TRAIL monotherapy. Third, so far patients enrolled in TRA-employing clinical trials were not selected for likelihood of benefitting from a TRA-comprising therapy on the basis of a valid(ated) biomarker. This review summarizes and discusses the results achieved so far in TRA-employing clinical trials in the light of these three shortcomings. By integrating recent insight on apoptotic and non-apoptotic TRAIL signaling in cancer cells, we propose approaches to introduce novel, revised TRAIL-based therapeutic concepts into the cancer clinic. These include (i) the use of recently developed highly active TRAs, (ii) the addition of efficient, but cancer-cell-selective TRAIL-sensitizing agents to overcome TRAIL resistance and (iii) employing proteomic profiling to uncover resistance mechanisms. We envisage that this shall enable the design of effective TRA-comprising therapeutic concepts for individual cancer patients in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
De Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,136
An endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532
The Pathophysiology of Mitochondrial Cell Death
Green, D. R., & Kroemer, G. (2004) · Science · doi:10.1126/science.1099320 · Cited by 3,418
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Two CD95 (APO‐1/Fas) signaling pathways
Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K., Krammer, P. H., & Peter, M. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.6.1675 · Cited by 3,000
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S.-I., Sameshima, M., Hase, A., Seto, Y., & Nagata, S. (1991) · Cell · doi:10.1016/0092-8674(91)90614-5 · Cited by 2,737
Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase
Sun, L., Wang, H., Wang, Z., He, S., Chen, S., Liao, D., Wang, L., Yan, J., Liu, W., Lei, X., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.031 · Cited by 2,698
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Self-citationVerhagen, A. M., Ekert, P. G., Pakusch, M., Silke, J., Connolly, L. M., Reid, G. E., Moritz, R. L., Simpson, R. J., & Vaux, D. L. (2000) · Cell · doi:10.1016/s0092-8674(00)00009-x · Cited by 2,372
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 1×
“Hence, most cancer cells are either primarily resistant or acquire resistance to these conventional therapies.(5) The extrinsic apoptosis pathways are triggered by binding of death ligands to transmembrane receptors, so-called death receptors (DRs), thereby transmitting a death signal coming from the outside of the ce…”
BackgroundABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
X-linked IAP is a direct inhibitor of cell-death proteases
Deveraux, Q. L., Takahashi, R., Salvesen, G. S., & Reed, J. C. (1997) · Nature · doi:10.1038/40901 · Cited by 1,955
Holler, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., Bodmer, J.-L., Schneider, P., Seed, B., & Tschopp, J. (2000) · Nature Immunology · doi:10.1038/82732 · Cited by 1,938
Tumour necrosis factor and cancer
Balkwill, F. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2628 · Cited by 1,915
Lethal effect of the anti-Fas antibody in mice
Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., & Nagata, S. (1993) · Nature · doi:10.1038/364806a0 · Cited by 1,881
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793
The Receptor for the Cytotoxic Ligand TRAIL
Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., & Dixit, V. M. (1997) · Science · doi:10.1126/science.276.5309.111 · Cited by 1,767
Monoclonal Antibody-Mediated Tumor Regression by Induction of Apoptosis
Trauth, B. C., Klas, C., Peters, A. M. J., Matzku, S., Möller, P., Falk, W., Debatin, K.-M., & Krammer, P. H. (1989) · Science · doi:10.1126/science.2787530 · Cited by 1,716
Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors
Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., et al. (1997) · Science · doi:10.1126/science.277.5327.818 · Cited by 1,664
An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL
Pan, G., Ni, J., Wei, Y.-F., Yu, G.-L., Gentz, R., & Dixit, V. M. (1997) · Science · doi:10.1126/science.277.5327.815 · Cited by 1,496
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469
Yonehara, S., Ishii, A., & Yonehara, M. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.5.1747 · Cited by 1,400
Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis
Cai, Z., Jitkaew, S., Zhao, J., Chiang, H.-C., Choksi, S., Liu, J., Ward, Y., Wu, L.-G., & Liu, Z.-G. (2014) · Nature Cell Biology · doi:10.1038/ncb2883 · Cited by 1,322
Catalytic activity of the caspase-8–FLIPL complex inhibits RIPK3-dependent necrosis
Oberst, A., Dillon, C. P., Weinlich, R., McCormick, L. L., Fitzgerald, P., Pop, C., Hakem, R., Salvesen, G. S., & Green, D. R. (2011) · Nature · doi:10.1038/nature09852 · Cited by 1,278 · cited 3×
“Recently, it was demonstrated that DR triggering may also program cells to die in a caspase-independent, necrotic way (known as programmed necrosis or necroptosis).63 Necroptosis depends on the formation of a complex containing the kinases RIP1 and RIP3.”
BackgroundThe Pseudokinase MLKL Mediates Necroptosis via a Molecular Switch Mechanism
Murphy, J. M., Czabotar, P. E., Hildebrand, J. M., Lucet, I. S., Zhang, J.-G., Alvarez-Diaz, S., Lewis, R., Lalaoui, N., Metcalf, D., Webb, A. I., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.018 · Cited by 1,220
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,184
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL
Walczak, H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5386 · Cited by 1,130
Self-citationLinkermann, A., & Green, D. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1310050 · Cited by 1,103
KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene
Wu, G. S., Burns, T. F., McDonald, E. R., Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-141 · Cited by 1,083
Yang, Y., Fang, S., Jensen, J. P., Weissman, A. M., & Ashwell, J. D. (2000) · Science · doi:10.1126/science.288.5467.874 · Cited by 988
Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5
Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., & Ashkenazi, A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80212-5 · Cited by 975
Feoktistova, M., Geserick, P., Kellert, B., Dimitrova, D. P., Langlais, C., Hupe, M., Cain, K., MacFarlane, M., Häcker, G., & Leverkus, M. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.06.011 · Cited by 860
Oehm, A., Behrmann, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Weber, M., Richards, S., Dhein, J., & Trauth, B. C. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50076-x · Cited by 834
Degli-Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. A., & Goodwin, R. G. (1997) · Immunity · doi:10.1016/s1074-7613(00)80399-4 · Cited by 821
Sprick, M. R., Weigand, M. A., Rieser, E., Rauch, C. T., Juo, P., Blenis, J., Krammer, P. H., & Walczak, H. (2000) · Immunity · doi:10.1016/s1074-7613(00)80211-3 · Cited by 794
Self-citationIAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer
Gyrd-Hansen, M., & Meier, P. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2889 · Cited by 790
Chen, X., Li, W., Ren, J., Huang, D., He, W.-T., Song, Y., Yang, C., Li, W., Zheng, X., Chen, P., et al. (2014) · Cell Research · doi:10.1038/cr.2013.171 · Cited by 779
Fulda, S., Wick, W., Weller, M., & Debatin, K.-M. (2002) · Nature Medicine · doi:10.1038/nm735 · Cited by 741
Mitochondria: master regulators of danger signalling
Galluzzi, L., Kepp, O., & Kroemer, G. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3479 · Cited by 733
Maximizing mouse cancer models
Frese, K. K., & Tuveson, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2192 · Cited by 717
Mechanisms of Action of Bcl-2 Family Proteins
Shamas-Din, A., Kale, J., Leber, B., & Andrews, D. W. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008714 · Cited by 705
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
Lacey, D. L., Boyle, W. J., Simonet, W. S., Kostenuik, P. J., Dougall, W. C., Sullivan, J. K., Martin, J. S., & Dansey, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3705 · Cited by 694
A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell Death
Li, L., Thomas, R. M., Suzuki, H., De Brabander, J. K., Wang, X., & Harran, P. G. (2004) · Science · doi:10.1126/science.1098231 · Cited by 656
A novel receptor for Apo2L/TRAIL contains a truncated death domain
Marsters, S. A., Sheridan, J. P., Pitti, R. M., Huang, A., Skubatch, M., Baldwin, D., Yuan, J., Gurney, A., Goddard, A. D., Godowski, P., et al. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00422-2 · Cited by 653
Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family
Degli-Esposti, M. A., Smolak, P. J., Walczak, H., Waugh, J., Huang, C.-P., DuBose, R. F., Goodwin, R. G., & Smith, C. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.1165 · Cited by 629
Self-citationWagner, K. W., Punnoose, E. A., Januario, T., Lawrence, D. A., Pitti, R. M., Lancaster, K., Lee, D., von Goetz, M., Yee, S. F., Totpal, K., et al. (2007) · Nature Medicine · doi:10.1038/nm1627 · Cited by 612
IAPs, RINGs and ubiquitylation
Vaux, D. L., & Silke, J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1621 · Cited by 610
Jin, Z., Li, Y., Pitti, R., Lawrence, D., Pham, V. C., Lill, J. R., & Ashkenazi, A. (2009) · Cell · doi:10.1016/j.cell.2009.03.015 · Cited by 591
Krueger, A., Schmitz, I., Baumann, S., Krammer, P. H., & Kirchhoff, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101780200 · Cited by 566
c-FLIPL is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis
Chang, D. W. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf356 · Cited by 563
Kischkel, F. C., Lawrence, D. A., Tinel, A., LeBlanc, H., Virmani, A., Schow, P., Gazdar, A., Blenis, J., Arnott, D., & Ashkenazi, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105102200 · Cited by 536
Recent advances in apoptosis, mitochondria and drug resistance in cancer cells
Indran, I. R., Tufo, G., Pervaiz, S., & Brenner, C. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.03.010 · Cited by 526
LeBlanc, H., Lawrence, D., Varfolomeev, E., Totpal, K., Morlan, J., Schow, P., Fong, S., Schwall, R., Sinicropi, D., & Ashkenazi, A. (2002) · Nature Medicine · doi:10.1038/nm0302-274 · Cited by 507
Caspase-8 and Bid: Caught in the act between death receptors and mitochondria
Kantari, C., & Walczak, H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.026 · Cited by 502
Self-citationMechanisms of CD95 (APO-1/Fas)-mediated apoptosis
Peter, M. E., & Krammer, P. H. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80222-7 · Cited by 498
XIAP discriminates between type I and type II FAS-induced apoptosis
Jost, P. J., Grabow, S., Gray, D., McKenzie, M. D., Nachbur, U., Huang, D. C. S., Bouillet, P., Thomas, H. E., Borner, C., Silke, J., et al. (2009) · Nature · doi:10.1038/nature08229 · Cited by 482
The Long Form of FLIP Is an Activator of Caspase-8 at the Fas Death-inducing Signaling Complex
Micheau, O., Thome, M., Schneider, P., Holler, N., Tschopp, J., Nicholson, D. W., Briand, C., & Grütter, M. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206882200 · Cited by 482
Molecular biology of Bax and Bak activation and action
Westphal, D., Dewson, G., Czabotar, P. E., & Kluck, R. M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.12.019 · Cited by 453
Herbst, R. S., Eckhardt, S. G., Kurzrock, R., Ebbinghaus, S., O'Dwyer, P. J., Gordon, M. S., Novotny, W., Goldwasser, M. A., Tohnya, T. M., Lum, B. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1991 · Cited by 446
Westphal, D., Kluck, R. M., & Dewson, G. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.139 · Cited by 431
Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog.
Tracey, K. J., Lowry, S. F., Fahey, T. J., Albert, J. D., Fong, Y., HESSE, D. G., Beutler, B., Manogue, K. R., Calvano, S. E., & Hu, W. M. (1987) · PubMed · Cited by 429
The Human Anti-apoptotic Proteins cIAP1 and cIAP2 Bind but Do Not Inhibit Caspases
Eckelman, B. P., & Salvesen, G. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510863200 · Cited by 391
Sprick, M. R. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf441 · Cited by 363
TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation
Jouan-Lanhouet, S., Arshad, M. I., Piquet-Pellorce, C., Martin-Chouly, C., Le Moigne-Muller, G., Van Herreweghe, F., Takahashi, N., Sergent, O., Lagadic-Gossmann, D., Vandenabeele, P., et al. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2012.90 · Cited by 357
Dickens, L. S., Boyd, R. S., Jukes-Jones, R., Hughes, M. A., Robinson, G. L., Fairall, L., Schwabe, J. W. R., Cain, K., & MacFarlane, M. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.05.004 · Cited by 349
Inhibitor of Apoptosis (IAP) Proteins-Modulators of Cell Death and Inflammation
Silke, J., & Meier, P. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008730 · Cited by 332
TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL
Screaton, G. R., Mongkolsapaya, J., Xu, X.-N., Cowper, A. E., McMichael, A. J., & Bell, J. I. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00297-1 · Cited by 325
TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling
Pan, G., Ni, J., Yu, G.-L., Wei, Y.-F., & Dixit, V. M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00135-5 · Cited by 317
Tolcher, A. W., Mita, M., Meropol, N. J., von Mehren, M., Patnaik, A., Padavic, K., Hill, M., Mays, T., McCoy, T., Fox, N. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8898 · Cited by 314
Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2
Mérino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, E., & Micheau, O. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00520-06 · Cited by 305
Characterization of two receptors for TRAIL1
Schneider, P., Bodmer, J.-L., Thome, M., Hofmann, K., Holler, N., & Tschopp, J. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01231-3 · Cited by 290
Kelley, R. F., Totpal, K., Lindstrom, S. H., Mathieu, M., Billeci, K., DeForge, L., Pai, R., Hymowitz, S. G., & Ashkenazi, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410660200 · Cited by 284
c-FLIPR, a New Regulator of Death Receptor-induced Apoptosis
Golks, A., Brenner, D., Fritsch, C., Krammer, P. H., & Lavrik, I. N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414425200 · Cited by 282
Dhein, J., Daniel, P. T., Trauth, B. C., Oehm, A., Möller, P., & Krammer, P. H. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.10.3166 · Cited by 278
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis
Hinz, S., Trauzold, A., Boenicke, L., Sandberg, C., Beckmann, S., Bayer, E., Walczak, H., Kalthoff, H., & Ungefroren, H. (2000) · Oncogene · doi:10.1038/sj.onc.1203936 · Cited by 275
Self-citationWilson, N. S., Yang, B., Yang, A., Loeser, S., Marsters, S., Lawrence, D., Li, Y., Pitti, R., Totpal, K., Yee, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.012 · Cited by 248
Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
Plummer, R., Attard, G., Pacey, S., Li, L., Razak, A., Perrett, R., Barrett, M., Judson, I., Kaye, S., Fox, N. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0950 · Cited by 247
Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment
Geserick, P., Hupe, M., Moulin, M., Wong, W. W.-L., Feoktistova, M., Kellert, B., Gollnick, H., Silke, J., & Leverkus, M. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200904158 · Cited by 246
Soria, J.-C., Márk, Z., Zatloukal, P., Szima, B., Albert, I., Juhász, E., Pujol, J.-L., Kozielski, J., Baker, N., Smethurst, D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2623 · Cited by 246
Temperature-sensitive Differential Affinity of TRAIL for Its Receptors
Truneh, A., Sharma, S., Silverman, C., Khandekar, S., Reddy, M. P., Deen, K. C., Mclaughlin, M. M., Srinivasula, S. M., Livi, G. P., Marshall, L. A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m910438199 · Cited by 245
Vince, J. E., Pantaki, D., Feltham, R., Mace, P. D., Cordier, S. M., Schmukle, A. C., Davidson, A. J., Callus, B. A., Wong, W. W.-L., Gentle, I. E., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.072256 · Cited by 241
Self-citationShipman, C. M., & Croucher, P. I. (2003) · PubMed · Cited by 241
Wu, G. S., Burns, T. F., Zhan, Y.-A., Alnemri, E. S., & El‐Deiry, W. S. (1999) · PubMed · Cited by 238
Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4
Todaro, M., Lombardo, Y., Francipane, M. G., Alea, M. P., Cammareri, P., Iovino, F., Di Stefano, A. B., Di Bernardo, C., Agrusa, A., Condorelli, G., et al. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402305 · Cited by 233
Self-citationWANG, S., & FISCHER, P. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.03.003 · Cited by 232
Clancy, L., Mruk, K., Archer, K., Woelfel, M., Mongkolsapaya, J., Screaton, G., Lenardo, M. J., & Chan, F. K.-M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507329102 · Cited by 232
Soria, J.-C., Smit, E., Khayat, D., Besse, B., Yang, X., Hsu, C.-P., Reese, D., Wiezorek, J., & Blackhall, F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4847 · Cited by 231
TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma
Trauzold, A., Siegmund, D., Schniewind, B., Sipos, B., Egberts, J., Zorenkov, D., Emme, D., Röder, C., Kalthoff, H., & Wajant, H. (2006) · Oncogene · doi:10.1038/sj.onc.1209719 · Cited by 219
Ganten, T. M., Koschny, R., Sykora, J., Schulze-Bergkamen, H., Büchler, P., Haas, T. L., Schader, M. B., Untergasser, A., Stremmel, W., & Walczak, H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2635 · Cited by 217
Self-citationSchleich, K., Warnken, U., Fricker, N., Öztürk, S., Richter, P., Kammerer, K., Schnölzer, M., Krammer, P. H., & Lavrik, I. N. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.05.006 · Cited by 198
Kindler, H. L., Richards, D. A., Garbo, L. E., Garon, E. B., Stephenson, J. J., Rocha-Lima, C. M., Safran, H., Chan, D., Kocs, D. M., Galimi, F., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds142 · Cited by 193
BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane
Schug, Z. T., Gonzalvez, F., Houtkooper, R. H., Vaz, F. M., & Gottlieb, E. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2010.135 · Cited by 190
Hotte, S. J., Hirte, H. W., Chen, E. X., Siu, L. L., Le, L. H., Corey, A., Iacobucci, A., MacLean, M., Lo, L., Fox, N. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1416 · Cited by 190
Cachetin/TNF-α in Septic Shock and Septic Adult Respiratory Distress Syndrome
Tracey, K. J., Lowry, S. F., & Cerami, A. (1988) · American Review of Respiratory Disease · doi:10.1164/ajrccm/138.6.1377 · Cited by 185
Clohessy, J. G., Zhuang, J., de Boer, J., Gil-Gómez, G., & Brady, H. J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m505688200 · Cited by 184
Trarbach, T., Moehler, M., Heinemann, V, Köhne, C.-H., Przyborek, M., Schulz, C., Sneller, V, Gallant, G., & Kanzler, S. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605507 · Cited by 180
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Cited by 180
Azijli, K., Weyhenmeyer, B., Peters, G. J., de Jong, S., & Kruyt, F. A. E. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2013.28 · Cited by 178
Systemic use of tumor necrosis factor alpha as an anticancer agent
Roberts, N. J., Zhou, S., Diaz, L. A., & Holdhoff, M. (2011) · Oncotarget · doi:10.18632/oncotarget.344 · Cited by 177
Choi, Y. E., Butterworth, M., Malladi, S., Duckett, C. S., Cohen, G. M., & Bratton, S. B. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807550200 · Cited by 177
Camidge, D. R., Herbst, R. S., Gordon, M. S., Eckhardt, S. G., Kurzrock, R., Durbin, B., Ing, J., Tohnya, T. M., Sager, J., Ashkenazi, A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1267 · Cited by 169
Greco, F. A., Bonomi, P., Crawford, J., Kelly, K., Oh, Y., Halpern, W., Lo, L., Gallant, G., & Klein, J. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.12.011 · Cited by 168
TRAIL Receptor-Selective Mutants Signal to Apoptosis via TRAIL-R1 in Primary Lymphoid Malignancies
MacFarlane, M., Kohlhaas, S. L., Sutcliffe, M. J., Dyer, M. J. S., & Cohen, G. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2801 · Cited by 163
TRAF2 Sets a Threshold for Extrinsic Apoptosis by Tagging Caspase-8 with a Ubiquitin Shutoff Timer
Gonzalvez, F., Lawrence, D., Yang, B., Yee, S., Pitti, R., Marsters, S., Pham, V. C., Stephan, J.-P., Lill, J., & Ashkenazi, A. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.09.031 · Cited by 162
Wakelee, H. A., Patnaik, A., Sikic, B. I., Mita, M. M., Fox, N. L., Miceli, R. C., Ullrich, S. J., Fisher, G. A., & Tolcher, A. W. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp292 · Cited by 157
Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1
MacFarlane, M., Inoue, S., Kohlhaas, S. L., Majid, A., Harper, N. W., Kennedy, D. B., Dyer, M. J. S., & Cohen, G. M. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401649 · Cited by 156
Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells
Ishimura, N., Isomoto, H., Bronk, S. F., & Gores, G. J. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00242.2005 · Cited by 155
Sheikh, M. S., Huang, Y., Fernández‐Salas, E., El‐Deiry, W. S., Friess, H., Amundson, S. A., Yin, J., Meltzer, S. J., Holbrook, N. J., & Fornace, A. J. (1999) · Oncogene · doi:10.1038/sj.onc.1202763 · Cited by 150
Hoogwater, F. J. H., Nijkamp, M. W., Smakman, N., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.046 · Cited by 147
Forero, A., Shah, J. J., Wood, T. E., Posey, J. A., Carlisle, R. R., Copigneaux, C., Luo, F. M., Wojtowicz‐Praga, S., Percent, I. J., & Saleh, M. N. (2010) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0673 · Cited by 145
A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
Herbst, R. S., Kurzrock, R., Hong, D. S., Valdivieso, M., Hsu, C., Goyal, L., Juan, G., Hwang, Y. C., Wong, S., Hill, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0631 · Cited by 144
Mongkolsapaya, J., Cowper, A., Xu, X., Morris, G. M., McMichael, A. J., Bell, J. I., & Screaton, G. R. (1998) · PubMed · Cited by 140
Fakler, M., Loeder, S., Vogler, M., Schneider, K., Jeremias, I., Debatin, K., & Fulda, S. (2008) · Blood · doi:10.1182/blood-2007-09-114314 · Cited by 138
Is TRAIL the holy grail of cancer therapy?
Newsom-Davis, T. E., Prieske, S., & Walczak, H. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0321-2 · Cited by 137
Self-citationSchneider, P., Olson, D. L., Tardivel, A., Browning, B., Lugovskoy, A. A., Gong, D., Dobles, M., Hertig, S., Hofmann, K., van Vlijmen, H., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210783200 · Cited by 136
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
Younes, A., Vose, J. M., Zelenetz, A. D., Smith, M. R., Burris, H. A., Ansell, S. M., Klein, J., Halpern, W., Miceli, R. C., Kumm, E., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605987 · Cited by 132
Haselmann, V., Kurz, A., Bertsch, U., Hübner, S., Olempska-Müller, M., Fritsch, J., Häsler, R., Pickl, A., Fritsche, H., Annewanter, F., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.009 · Cited by 124
Self-citationSelective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
Lemke, J., von Karstedt, S., Hay, M. Y. A. E., Conti, A., Vargas, F. A., Montinaro, A., Papenfuss, K., El-Bahrawy, M. A., & Walczak, H. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.179 · Cited by 124
Self-citationLeong, S., Cohen, R. B., Gustafson, D. L., Langer, C. J., Camidge, D. R., Padavic, K., Gore, L., Smith, M., Chow, L. Q. M., von Mehren, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7422 · Cited by 123
Huang, S., & Sinicrope, F. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2508 · Cited by 122
Gieffers, C., Kluge, M., Merz, C., Sykora, J., Thiemann, M., Schaal, R., Fischer, C., Branschädel, M., Abhari, B. A., Hohenberger, P., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0323 · Cited by 121
Structural Basis for the Lack of E2 Interaction in the RING Domain of TRAF2
Yin, Q., Lamothe, B., Darnay, B. G., & Wu, H. (2009) · Biochemistry · doi:10.1021/bi901462e · Cited by 119
TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2
Munshi, A., Pappas, G., Honda, T., McDonnell, T. J., Younes, A., Li, Y., & Meyn, R. E. (2001) · Oncogene · doi:10.1038/sj.onc.1204504 · Cited by 119
Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors
Merchant, M. S., Geller, J. I., Baird, K., Chou, A. J., Galli, S., Charles, A., Amaoko, M., Rhee, E. H., Price, A. P., Wexler, L. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1055 · Cited by 118
Cellular FLICE-like inhibitory proteins (c-FLIPs): Fine-tuners of life and death decisions
Öztürk, S., Schleich, K., & Lavrik, I. N. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.01.019 · Cited by 116
Mongkolsapaya, J., Cowper, A. E., Xu, X., Morris, G. M., McMichael, A. J., Bell, J. I., & Screaton, G. R. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.1.3 · Cited by 116
Fulda, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0227 · Cited by 107
Mom, C. H., Verweij, J., Oldenhuis, C. N. A. M., Gietema, J. A., Fox, N. L., Miceli, R. C., Eskens, F. A. L. M., Loos, W. J., de Vries, E. G. E., & Sleijfer, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0996 · Cited by 106
Death receptor agonist therapies for cancer, which is the right TRAIL?
Holland, P. M. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.12.009 · Cited by 100
von Pawel, J., Harvey, J. H., Spigel, D. R., Dediu, M., Reck, M., Cebotaru, C. L., Humphreys, R. C., Gribbin, M., Fox, N. L., & Camidge, D. R. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.12.005 · Cited by 99
Cohn, A. L., Tabernero, J. M., Maurel, J., Nowara, E., Sastre, J., Chuah, B., Валериевич, К. М., Sakaeva, D., Mitchell, E. P., Dubey, S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt057 · Cited by 94
DuPage, M. J. P., & Jacks, T. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.02.005 · Cited by 92
Forero, A., Infante, J. R., Waterhouse, D. M., Wong, L., Vickers, S. M., Arrowsmith, E. R., He, A. R., Hart, L. L., Trent, D. F., Wade, J. L., et al. (2013) · Cancer Medicine · doi:10.1002/cam4.137 · Cited by 90
Ganten, T. M., Sykora, J., Koschny, R., et al. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0510-z · Cited by 86
Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level
Morizot, A., Mérino, D., Lalaoui, N., Jacquemin, G., Granci, V., Iessi, E., Lanneau, D., Bouyer, F., Solary, É., Chauffert, B., et al. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.144 · Cited by 82
Lemke, J., Noack, A., Adam, D., Tchikov, V., Bertsch, U., Röder, C., Schütze, S., Wajant, H., Kalthoff, H., & Trauzold, A. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0619-0 · Cited by 81
Self-citationLalaoui, N., Morlé, A., Mérino, D., Jacquemin, G., Iessi, E., Morizot, A., Shirley, S., Robert, B., Solary, É., Garrido, C., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019679 · Cited by 78
Lecis, D., Drago, C., Manzoni, L., Seneci, P., Scolastico, C., Mastrangelo, E., Bolognesi, M., Anichini, A., Kashkar, H., Walczak, H., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605687 · Cited by 77
Self-citationBortezomib and TRAIL: A perfect match for apoptotic elimination of tumour cells?
de Wilt, L. H. A. M., Kroon, J., Jansen, G., de Jong, S., Peters, G. J., & Kruyt, F. A. E. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.08.001 · Cited by 75
Paz-Ares, L. G., Bálint, B., Boer, R. H. D., van Meerbeeck, J. P., Wierzbicki, R. F., SOUZA, P. D., Galimi, F., Haddad, V., Sabin, T., Hei, Y.-J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827ce554 · Cited by 74
Miyashita, T., Kawakami, A., Nakashima, T., Yamasaki, S., Tamai, M., Tanaka, F., Kamachi, M., Ida, H., Migita, K., Origuchi, T., et al. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02534.x · Cited by 74
Demetri, G. D., Cesne, A. L., Chawla, S. P., Brodowicz, T., Maki, R. G., Bach, B. A., Smethurst, D. P., Bray, S. L., Hei, Y.-J., & Blay, J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.008 · Cited by 68
Yee, L., Fanale, M. A., Dimick, K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8078 · Cited by 68
Fuchs, C. S., Fakih, M., Schwartzberg, L. S., Cohn, A. L., Yee, L., Dreisbach, L. P., Kozloff, M. F., Hei, Y.-J., Galimi, F., Pan, Y., et al. (2013) · Cancer · doi:10.1002/cncr.28353 · Cited by 66
Wilson, N. S., Yang, A., Yang, B., Couto, S. S., Stern, H. M., Gogineni, A., Pitti, R. M., Marsters, S. A., Weimer, R. M., Singh, M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.014 · Cited by 66
Subbiah, V., Brown, R. E., Buryanek, J., Trent, J. C., Ashkenazi, A., Herbst, R. S., & Kurzrock, R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0358 · Cited by 66
CD95 (Fas/APO-1) and p53 signal apoptosis independently in diverse cell types.
O’Connor, L., Harris, A. W., & Strasser, A. (2000) · PubMed · Cited by 62
Haynes, N. M., Hawkins, E. D., Li, M., McLaughlin, N. M., Hämmerling, G. J., Schwendener, R. A., Winoto, A., Wensky, A. K., Yagita∥, H., Takeda, K., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903624 · Cited by 61
TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells
Voigt, S., Philipp, S., Davarnia, P., Winoto‐Morbach, S., Röder, C., Arenz, C., Trauzold, A., Kabelitz, D., Schütze, S., Kalthoff, H., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-74 · Cited by 61
Wainberg, Z. A., Messersmith, W. A., Peddi, P. F., Kapp, A. V., Ashkenazi, A., Royer‐Joo, S., Portera, C. C., & Kozloff, M. F. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.06.002 · Cited by 60
Wang, H., Davis, J. S., & Wu, X. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0645 · Cited by 58
Sharma, S., de Vries, E. G. E., Infante, J. R., Oldenhuis, C. N. A. M., Gietema, J. A., Yang, L., Bilic, S., Parker, K., Goldbrunner, M., Scott, J. W., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9952-9 · Cited by 51
Doi, T., Murakami, H., Ohtsu, A., Fuse, N., Yoshino, T., Yamamoto, N., Boku, N., Onozawa, Y., Hsu, C.-P., Gorski, K. S., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1544-1 · Cited by 50
Reck, M., Krzakowski, M. J., Chmielowska, E., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.09.014 · Cited by 49
Sikic, B. I., Wakelee, H. A., von Mehren, M., Lewis, N. L., Calvert, H., Plummer, E. R., Fox, N. L., Howard, T., Jones, S. F., & Burris, H. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.14006 · Cited by 49
Cristofanon, S., & Fulda, S. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.163 · Cited by 48
Lima, C. M. R., Bayraktar, S., Flores, A. M., MacIntyre, J., Montero, A. J., Baranda, J. C., Wallmark, J. M., Portera, C. C., Raja, R. G., Stern, H. M., et al. (2012) · Cancer Investigation · doi:10.3109/07357907.2012.732163 · Cited by 47
Active transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family
Schilling, T., Schleithoff, E. S., Kairat, A., Melino, G., Stremmel, W., Oren, M., Krammer, P. H., & Müller, M. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.07.063 · Cited by 43
Tuettenberg, J., Seiz, M., Debatin, K., Hollburg, W., von Staden, M., Thiemann, M., Hareng, B., Fricke, H., & Kunz, C. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.03.004 · Cited by 38
Sikic, B. I., Wakelee, H. A., von Mehren, M., Lewis, N. L., Plummer, E. R., Calvert, H., Fox, N. L., Kumm, E., Jones, S. F., & Burris, H. A. (2007) · UCL Discovery (University College London) · Cited by 36
IAPs – the ubiquitin connection
Vaux, D. L., & Silke, J. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401696 · Cited by 36
Passante, E., Würstle, M. L., Hellwig, C. T., Leverkus, M., & Rehm, M. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.106 · Cited by 35
Yee, L., Burris, H. A., Kozloff, M. F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.4129 · Cited by 31
Belada, D., Mayer, J., Czuczman, M. S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8104 · Cited by 26
Belch, A. R., Sharma, A., Spencer, A. G., et al. (2010) · Blood · doi:10.1182/blood.v116.21.5031.5031 · Cited by 22
Chawla, S. P., Tabernero, J. M., Kindler, H. L., Chiorean, E. G., LoRusso, P. M., Hsu, M., Haddad, V., Bach, B. A., & Baselga, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3102 · Cited by 14
Kasubhai, S. M., Bendell, J. C., Kozloff, M. F., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.3543 · Cited by 14
Cited by
Tumour-associated neutrophils in patients with cancer
Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,023
Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics
Jan, R., & Chaudhry, G.-E.-S. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.024 · Cited by 899
Nedeljković, M., & Damjanović, A. (2019) · Cells · doi:10.3390/cells8090957 · Cited by 870
Mitochondrial apoptosis: killing cancer using the enemy within
Lopez, J., & Tait, S. W. G. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.85 · Cited by 784
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
Roybal, K. T., Williams, J. Z., Morsut, L., Rupp, L. J., Kolinko, I., Choe, J. H., Walker, W. J., McNally, K. A., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.09.011 · Cited by 721
Metadata
- Authors
- Lemke, J., von Karstedt, S., Zinngrebe, J., & Walczak, H.
- Venue
- Cell Death & Differentiation
- Published
- 2014-06-20
- Volume
- 21
- Issue
- 9
- Pages
- 1350-1364
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W2171139000
- Cited by
- 457
- References
- 172
- FWCI
- 20.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.